266 related articles for article (PubMed ID: 31783010)
1. Overcoming Taxol-resistance in A549 cells: A comprehensive strategy of targeting P-gp transporter, AKT/ERK pathways, and cytochrome P450 enzyme CYP1B1 by 4-hydroxyemodin.
Lin H; Hu B; He X; Mao J; Wang Y; Wang J; Zhang T; Zheng J; Peng Y; Zhang F
Biochem Pharmacol; 2020 Jan; 171():113733. PubMed ID: 31783010
[TBL] [Abstract][Full Text] [Related]
2. Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resistance.
Yao X; Mao J; Zhang H; Xiao Y; Wang Y; Liu H
Eur J Med Chem; 2024 Jun; 272():116488. PubMed ID: 38733885
[TBL] [Abstract][Full Text] [Related]
3. Structure-Based Drug Design and Synthesis of Novel
Mao J; Wang D; Xu P; Wang Y; Zhang H; Wang S; Xu F; Wang J; Zhang F
J Med Chem; 2022 Dec; 65(24):16451-16480. PubMed ID: 36512763
[TBL] [Abstract][Full Text] [Related]
4. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
5. Pregnane X receptors regulate CYP2C8 and P-glycoprotein to impact on the resistance of NSCLC cells to Taxol.
Chen Y; Huang W; Chen F; Hu G; Li F; Li J; Xuan A
Cancer Med; 2016 Dec; 5(12):3564-3571. PubMed ID: 27878971
[TBL] [Abstract][Full Text] [Related]
6. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
Chen S; Zhang Z; Zhang J
Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158
[No Abstract] [Full Text] [Related]
7. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
8. Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells.
Bacon NA; Larre I; Lawag AA; Merritt C; Smith M; Rosolen M; Sollars VE
Biomed Pharmacother; 2020 Sep; 129():110434. PubMed ID: 32768937
[TBL] [Abstract][Full Text] [Related]
9. Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells.
Aldonza MB; Hong JY; Bae SY; Song J; Kim WK; Oh J; Shin Y; Lee SH; Lee SK
PLoS One; 2015; 10(6):e0127841. PubMed ID: 26098947
[TBL] [Abstract][Full Text] [Related]
10. Deoxyshikonin inhibits cisplatin resistance of non-small-cell lung cancer cells by repressing Akt-mediated ABCB1 expression and function.
Zhang S; Wang Y
J Biochem Mol Toxicol; 2020 Oct; 34(10):e22560. PubMed ID: 32627280
[TBL] [Abstract][Full Text] [Related]
11. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification.
Wang Y; He X; Li C; Ma Y; Xue W; Hu B; Wang J; Zhang T; Zhang F
Eur J Med Chem; 2020 May; 193():112235. PubMed ID: 32203789
[TBL] [Abstract][Full Text] [Related]
12. miR-339-5p downregulation contributes to Taxol resistance in small-cell lung cancer by targeting α1,2-fucosyltransferase 1.
Gan CZ; Li G; Luo QS; Li HM
IUBMB Life; 2017 Nov; 69(11):841-849. PubMed ID: 28940895
[TBL] [Abstract][Full Text] [Related]
13. RNAi targeting STMN alleviates the resistance to taxol and collectively contributes to down regulate the malignancy of NSCLC cells in vitro and in vivo.
Long D; Yu T; Chen X; Liao Y; Lin X
Cell Biol Toxicol; 2018 Feb; 34(1):7-21. PubMed ID: 28589243
[TBL] [Abstract][Full Text] [Related]
14. YAN, a novel microtubule inhibitor, inhibits P-gp and MRP1 function and induces mitotic slippage followed by apoptosis in multidrug-resistant A549/Taxol cells.
Gao M; Liu T; Li J; Guan Q; Wang H; Yan S; Li Z; Zuo D; Zhang W; Wu Y
Toxicol In Vitro; 2020 Dec; 69():104971. PubMed ID: 32805372
[TBL] [Abstract][Full Text] [Related]
15. A multiple-targets alkaloid nuciferine overcomes paclitaxel-induced drug resistance in vitro and in vivo.
Liu RM; Xu P; Chen Q; Feng SL; Xie Y
Phytomedicine; 2020 Dec; 79():153342. PubMed ID: 32992085
[TBL] [Abstract][Full Text] [Related]
16. Profiles and Bioinformatics Analysis of Differentially Expressed Circrnas in Taxol-Resistant Non-Small Cell Lung Cancer Cells.
Xu N; Chen S; Liu Y; Li W; Liu Z; Bian X; Ling C; Jiang M
Cell Physiol Biochem; 2018; 48(5):2046-2060. PubMed ID: 30099455
[TBL] [Abstract][Full Text] [Related]
17. The role of emodin on cisplatin resistance reversal of lung adenocarcinoma A549/DDP cell.
Teng X; Wang SY; Shi YQ; Fan XF; Liu S; Xing Y; Guo YY; Dong M
Anticancer Drugs; 2021 Oct; 32(9):939-949. PubMed ID: 34001704
[TBL] [Abstract][Full Text] [Related]
18. Autophagy inhibition with chloroquine reverts paclitaxel resistance and attenuates metastatic potential in human nonsmall lung adenocarcinoma A549 cells via ROS mediated modulation of β-catenin pathway.
Datta S; Choudhury D; Das A; Mukherjee DD; Dasgupta M; Bandopadhyay S; Chakrabarti G
Apoptosis; 2019 Jun; 24(5-6):414-433. PubMed ID: 30767087
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line.
Wang NN; Zhao LJ; Wu LN; He MF; Qu JW; Zhao YB; Zhao WZ; Li JS; Wang JH
Asian Pac J Cancer Prev; 2013; 14(9):4983-8. PubMed ID: 24175763
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Oncoprotein 18/Stathmin Signaling by ERK Concerns the Resistance to Taxol in Nonsmall Cell Lung Cancer Cells.
Lin X; Liao Y; Chen X; Long D; Yu T; Shen F
Cancer Biother Radiopharm; 2016 Mar; 31(2):37-43. PubMed ID: 26881937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
